Contact lens manufacturer Safigel acquired by Rome-based Bruno Pharmaceuticals

Article

Contact lens maker Safigel was acquired by Bruno Pharmaceuticals S.P.A., a privately held, family owned, Italian pharmaceutical company based in Rome.

Chicago-Contact lens maker Safigel announced that the company was recently acquired by Bruno Pharmaceuticals S.P.A., a privately held, family owned, Italian pharmaceutical company based in Rome.

According to Safigel, Bruno shares a kindred synergy with Safigel’s mission, “to provide new, groundbreaking alternatives to eye-care professionals (ECPs) who fit patients with contact lenses, and to stay on the cutting-edge of bringing major technological innovations to the eye-care marketplace that benefit contact lens wearers.”

According to Vincenzo Bruno, Italian Chief Executive Officer, the two companies will “offer even more” to U.S. ECPs in the coming months.

Although details of the transaction were not disclosed, Safigel said in a statement that it will now expand its sales and marketing efforts on its sodium hyaluronate contact lens, which has seen steady growth.

For more articles in this issue of InDispensable, click here.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
© 2025 MJH Life Sciences

All rights reserved.